Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Vitiligo-like lesions and immune checkpoint inhibition therapy: is it truly an adverse event exclusive to patients with melanoma?

Literature DB >> 29333653

Vitiligo-like lesions and immune checkpoint inhibition therapy: is it truly an adverse event exclusive to patients with melanoma?

E Rodríguez-Lomba¹, I Molina-López¹, R Suárez-Fernández¹, O Baniandrés-Rodríguez¹.

Abstract

Entities: Disease Species

Mesh：

Substances：

Year: 2018 PMID： 29333653 DOI： 10.1111/ced.13382

Source DB: PubMed Journal: Clin Exp Dermatol ISSN： 0307-6938 Impact factor: 3.470

Keyword Cloud
Cited

× No keyword cloud information.

5 in total

Review 1. Immune checkpoint inhibitor-related dermatologic adverse events.

Authors: Amaris N Geisler; Gregory S Phillips; Dulce M Barrios; Jennifer Wu; Donald Y M Leung; Andrea P Moy; Jeffrey A Kern; Mario E Lacouture
Journal: J Am Acad Dermatol Date: 2020-05-23 Impact factor: 11.527

2. Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

Authors: Gregory S Phillips; Jennifer Wu; Matthew D Hellmann; Michael A Postow; Naiyer A Rizvi; Azael Freites-Martinez; Donald Chan; Stephen Dusza; Robert J Motzer; Jonathan E Rosenberg; Margaret K Callahan; Paul B Chapman; Larisa Geskin; Adriana T Lopez; Vanessa A Reed; Gabriella Fabbrocini; Maria Carmela Annunziata; Oluwaseun Kukoyi; Aliyah Pabani; Chih-Hsun Yang; Wen-Hung Chung; Alina Markova; Mario E Lacouture
Journal: J Clin Oncol Date: 2019-06-19 Impact factor: 50.717

Vitiligo-like lesions and immune checkpoint inhibition therapy: is it truly an adverse event exclusive to patients with melanoma?

Review 1. Immune checkpoint inhibitor-related dermatologic adverse events.

2. Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

Review 3. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.

4. Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma.

Review 5. Targeting the PD-1/PD-L1 Axis in Human Vitiligo.